Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,193.00+0.69%ETH$2,416.18+0.62%GOLD$4,309.80-1.77%OIL$101.77-0.64%
Smart Investors Daily
PV

NASDAQ · PVLA

Palvella Therapeutics, Inc.

Healthcare · Biotechnology

$151.22

Up+$0.21 (+0.14%)

Updated Sep 16, 2026, 11:35 PM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.15B
P/E ratio
-28.63
Dividend yield
0.00%
52-week range
$100.00 – $161.38
Volume
215.63K
Avg. volume
211.26K

Price performance

PVLA price history

1M range · 20 trading sessions · Daily adjusted prices

PVLA closed at $151.22 after 20 trading sessions, up 0.53% for the selected period.

Last close
$151.22
Period change
+0.53%
Period low
$142.04
Period high
$157.24
Daily close
View OHLC price history
PVLA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$152.72$155.63$148.145$151.22215.63K
Sep 14, 2026$150.14$153.405$150.14$151.69223.05K
Sep 11, 2026$152.75$154.30$149.9825$150.13163.37K
Sep 10, 2026$148.43$151.365$147.10$150.39266.08K
Sep 9, 2026$147.26$155.00$145.91$151.34149.39K
Sep 8, 2026$153.42$157.93$151.58$152.28165.03K
Sep 4, 2026$152.95$157.45$152.95$157.24162.27K
Sep 3, 2026$152.95$155.92$150.755$155.47249.67K
Sep 2, 2026$153.76$157.00$149.68$152.95125.22K
Sep 1, 2026$150.00$152.065$148.68$150.55119.94K
Aug 31, 2026$147.95$152.89$143.47$152.59245.78K
Aug 28, 2026$148.65$153.28$148.35$149.97191.99K
Aug 27, 2026$154.04$156.04$149.04$150.33232.75K
Aug 26, 2026$148.18$154.745$144.22$154.33194.44K
Aug 25, 2026$148.59$151.54$145.14$148.24191.99K
Aug 24, 2026$141.78$146.69$136.06$145.75315.52K
Aug 21, 2026$145.55$146.92$138.54$142.04161.87K
Aug 20, 2026$145.32$148.35$139.92$142.58208.99K
Aug 19, 2026$156.77$157.065$142.115$149.96217.21K
Aug 18, 2026$152.36$154.56$149.05$150.42147.99K

Latest PVLA news

The latest Smart Investors Daily articles mentioning PVLA.

Stock researchCompany · Overview

PVLA research

Overview

Company profile and research snapshot.

Company profile

Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$141.67
Implied upside
—
Analysts
—
PVLA recent ratings
DateFirmRatingTarget
May 21, 2026Stephens & Co.Overweight—
May 21, 2026Chardan CapitalBuy—
May 12, 2026Stephens & Co.Overweight—
Mar 31, 2026Chardan CapitalBuy—
Mar 24, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer

Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas Leader in pediatric dermatology with nearly 20 years of distinguished clinical, research, and academic experience Longstanding Palvella clinical collaborator and QTORIN™ trial investigator brings deep understanding of the unmet needs in serious, rare skin diseases including vascular anomalies Dr. Treat to lead medical strategy as Palvella moves QTORIN™ rapamyci

Yahoo · Sep 2, 2026

Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences

WAYNE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in two upcoming healthcare investor c

Yahoo · Aug 31, 2026

Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and establish a new standard of care for an estimated more than 30,000 pediatric and adult patients living with microcystic lymphatic malformations in the U.S. FDA previously granted Breakthrough Therapy and Fast Track designations; QTORIN™ rapamycin has also received Orphan Drug designation Accelerating U.S. launch readiness for a potential commercial launch of QTORIN™ rapamycin in the first half of 2027, if approved W

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By